REG - hVIVO PLC - Directorate Change

hVIVOAnnouncement

18/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250718:nRSR5751Ra&default-theme=true

RNS Number : 5751R  hVIVO PLC  18 July 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Directorate Change

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and
the world leader in human challenge clinical trials, announces that the
Company has received notice of resignation from Tracey James as Non-Executive
Director of the Board with immediate effect. The Company can confirm that Ms
James' decision to resign from the Board is unrelated to the Company's
financial performance or outlook. The Company's trading update for H1 2025
will be issued on 22 July 2025 as previously announced.

 

The Nominations Committee has commenced a process to appoint a new independent
Non-Executive Director and the Company will announce the results of this
process in due course.

 

Separately, the Nominations Committee is progressing well in its process to
appoint a new independent Non-Executive Chair, a further announcement will be
made in due course.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings                   +44 (0)7980 541 893 / +44 (0)7407 804 654

 Lianne Applegarth                               +44 (0)7584 391 303

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is full-service Contract Research
Organisation (CRO) and the global leader in human challenge trials. The
company delivers end-to-end clinical development services to a diverse and
expanding client base, including seven of the world's ten largest biopharma
companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGMNGNDGKZZ